Fyarro

Active Ingredient(s): Sirolimus Albumin-Bound Nanoparticles
FDA Approved: * November 22, 2021
Pharm Company: * AADI BIOSCIENCE INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Fyarro Overview

Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease called lymphangioleiomyomatosis.[4][5][6] It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mTOR inhibitio...

Read more Fyarro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sirolimus

Recent Fyarro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sirolimus Albumin-Bound Nanoparticles
  • Powder: 100mg/vial
  • Solution: 1mg/ml
  • Tablet: 0.5mg, 1mg, 2mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Sirolimus Albumin-Bound Nanoparticles or a similar ingredient: (2 results)